Oncolytics Biotech has a treatment in development for breast, pancreatic, and anal cancer. Pharmaceutical Executive spoke with chief medical officer Thomas C. Heineman, MD, PhD, and vice president of business development Christophe Degois about the company’s pipeline and financial status.

Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today’s guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases.

This time around, we note that Sernova Biotherapeutics hired Pericles Calias as chief development officer and head of R&D. Previously, he served as interim chief development officer at Vibe Bio, in addition to doing consulting and board work.

Life Biosciences, the company co-founded by the Harvard study’s lead author Dr David Sinclair, is gearing up to launch the first ever partial epigenetic reprogramming candidate into the clinic this year.

In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering

Revolo Biotherapeutics is developing a synthetic peptide therapy that can potentially restore immune system homeostasis in EOE and other allergic diseases.

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders. Now it’s on the cusp of its first regulatory approval.

COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases